The granting of emergency use authorization by the U.S. FDA to Roche AG for its four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and respiratory syncytial virus will allow the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback